CapVest to acquire majority stake in STADA
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
First Indian company to follow global recommendations in accordance with the World Health Organisation (WHO)
At the end of the current inspection, a 'Form 483' was issued with 5 observations which are procedural in nature and no data integrity issues were reported
Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Saroglitazar was generally well tolerated, with overall adverse events generally balanced between Saroglitazar-treated and placebo-treated patients
The US generic market is crucial for Indian pharma, contributing about 35% to its total revenue, around US$ 10.7 billion
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
Earlier in July 2025, Dazublys has received the marketing authorisation in the European Union from the European Commission
        Subscribe To Our Newsletter & Stay Updated